Clinical Trial

Comparison of Different Operations for Siewert Type II Adenocarcinoma of Esophagogastric Junction

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated November 8, 2024 (before its estimated May 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
The incidence of esophagogastric junction has been increasing in recent years, and surgery is an important method for the treatment of adenoma at the esophagogastric junction. Currently, there is a great controversy about the surgical method of Siewert II, mainly choosing the right chest or the left chest for thoracic surgery. Therefore, it is of great significance to further study the surgical methods of Siewert II esophagogastric junction adenoma. Objective: To compare the safety, feasibility, and clinical efficacy of endoscopic Ivor-Lewis versus laparoscopic extended abdominal gastrectomy for Siewert type Ⅱadenocarcinoma at the resectable esophagogastric junction.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2022-04-29; most recent amendment 2024-11-06.
Status change: Not Yet Recruiting → Recruiting 2022-05-19
Trial Details
NCT Number NCT05356520
Lead Sponsor Xijing Hospital of Digestive Diseases
Collaborators: Tang-Du Hospital, Henan Provincial People's Hospital, General Hospital of Ningxia Medical University, First Affiliated Hospital Xi'an Jiaotong University, The First Affiliated Hospital of Shanxi Medical University
Conditions Siewert Type II Adenocarcinoma of Esophagogastric Junction
Enrollment 212 participants
Start Date 2022-05-01
Primary Completion 2025-05-31 (estimated)
Study Completion 2028-05-31 (estimated)
Updated on ClinicalTrials.gov 2024-11-08